Skip to main content

Table 2 Operative and postoperative data

From: ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study

VariablesALPPS vs. TSH/PVE analysis
ALPPS (n = 21)TSH/PVE (n = 37)p value
Operative data step 1
 Operative time step 1 (minutes)270 (215–303)195 (145–250).001
 Operative procedure step 1, n (%)  n.a.
  Left atypical023 (62) 
  Left lateral resection07 (19) 
  Right atypical02 (5) 
  Right posterior resection01 (3) 
  Right hepatectomy6 (29)2 (5) 
  Right hepatectomy plus atypical left4 (19)0 
  Right hepatectomy plus left lateral resection1 (5)0 
  Extended right hepatectomy3 (14)0 
  Extended right plus atypical left2 (10)0 
  Right trisectionectomy4 (19)0 
  Right trisectionectomy plus atypical left1 (5)0 
  Others02 (5) 
 Intraoperative blood transfusion step 1 (y/n)7 (33)/14 (67)6 (16)/31 (84).133
Inter-stage data
 Time interval between the stages (days)10 (8–14)57 (34–113)< .001
 Inter-stage chemotherapy (y/n)09 (24).014
 Inter-stage PVE (y/n)027 (73)< .001
 Rate of completion, n (%)20 (95)34 (92).629
 Reason for non-completion, n (%)  .323
  Insufficient hypertrophy1 (100)2 (67) 
  Progressive disease01 (33) 
Operative data step 2
 Operative time step 2 (minutes)123 (94–170)280 (240–319)< .001
 Operative procedure step 2, n (%)   
  ALPPS completion20 (100)0 
  Monosegment resection01 (3) 
  Left atypical01 (3) 
  Left hepatectomy01 (3) 
  Extended left hepatectomy01 (3) 
  Right atypical02 (6) 
  Right posterior resection02 (6) 
  Right hepatectomy017 (50) 
  Extended right hepatectomy07 (21) 
  Right trisectionectomy02 (6) 
 Intraoperative blood transfusion step 2 (y/n)11 (55)/9 (5)14 (41)/20 (59).325
Volumetric data
 Stage 1   
  TLV (ml)1672 (1589–2127)1574 (1366–1801).046
  TV (ml)45 (19–342)23 (13–60).077
  FLR (ml)534 (392–716)450 (378–560).364
  cFLR (%)29 (25–37)29 (25–36).869
 Stage 2   
  TLV (ml)2083 (1724–2399)1679 (1406–1775)< .001
  TV (ml)35 (19–103)26 (13–68).208
  FLR (ml)716 (504–954)655 (486–744).448
  cFLR (%)37 (30–47)31 (33–50).103
 Degree of hypertrophy (%)35 (23–62)45 (18–69).803
Postoperative data
 Intensive care step 1, days1 (1–2)0 (0–1)< .001
 Intensive care step 2, days1 (0–1)1 (1–1).044
 Hospitalization step 1 and 2, days32 (22–46)22 (17–28).009
 Clavien-Dindo stage 1 ≥ IIIa, n (%)2 (10)5 (14).654
 Clavien-Dindo stage 1 = V, n (%)00n.a.
 Clavien-Dindo stage 2 ≥ IIIa, n (%)13 (65)13 (38).057
 Clavien-Dindo stage 2 = V, n (%)2 (10)2 (6).577
Follow-up data
 R0 resection20 (100)30 (88).116
 Median RFS (95% CI), months19 (8–30)10 (6–14).050
 Median OS (95% CI), months28 (19–37)34 (25–43).963
  1. Data presented as median and interquartile range if not noted otherwise. Categorical data were compared using the chi-squared test, Fisher’s exact test, or linear-by-linear association according to scale and number of cases. Data derived from continuous variables of different groups were compared by Mann-Whitney U test. Oncological survival was compared by the log-rank test. Survival data were calculated under exclusion of perioperative mortality
  2. ALPPS associating liver partition and portal vein ligation for staged hepatectomy, cFLR calculated future liver remnant, FLR future liver remnant, OS overall survival, PVE portal vein embolization, RFS recurrence-free survival, TLV total liver volume, TV tumor volume